How do you pay?

How to pay the least

Ask for the cash price

Yuviwel

We didn’t find one.

  1. Ask your pharmacy for Yuviwel’s cash price, and one or two other pharmacies too.
  2. Yuviwel’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameYuviwel
Authorized genericnavepegritide
Regular genericnavepegritide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Yuviwel?
The original
–
–

Brand nameThe maker’s card

YUVIWEL Co-Pay Program (A·S·A·P)

Savings card from Ascendis Pharma Endocrinology

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on yuviwel.com 

Or call 1-844-442-7236.

In the maker’s words

“Eligible patients with commercial health insurance may pay as little as $0 per month for YUVIWEL.”

From the maker’s offer on yuviwel.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Yuviwel itself, from the same company, sold without the brand name, and usually for less. For now Yuviwel is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

YUVIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Source: the FDA label for Yuviwel (Ascendis Pharma Endocrinology, Inc.), March 25, 2026. Full label on DailyMed 

Good to know